The Heroic Dose, a one-day virtual conference hosted by Microdose Psychedelic Insights (and sponsored by Psychedelic Spotlight), will explore the use of psychedelic therapies to treat post-traumatic stress disorder (PTSD), substance abuse, and suicide among military veterans and first responders.
Experts in psychedelic therapy, including researchers, clinicians, companies, and advocates, will discuss implications of psychedelic-assisted therapies and their relevance to veterans, many of whom suffer from mental health problems and cognitive impairment associated with repeated trauma exposure and the nature of the exposure.
Guest speakers will also explore early research into psychedelic-assisted therapies with ketamine, ibogaine, psilocybin, MDMA, and 5-MeO-DMT. Many of the therapies have demonstrated rapid and profound efficacy in treating mental health conditions including anxiety, depression, PTSD, and substance use disorder in veterans and first responders.
The conference is scheduled for April 22, beginning at 8:45 a.m. EST, and is open to anyone who would like more comprehensive and interactive information from experts on psychedelic medicine for mental health disorders. Conference tickets cost $50, and includes lifetime free access to all recordings. Veterans and first responders can attend for free by entering the code “VETERANS” at checkout. For more information, visit The Heroic Dose page here.
The conference comes just as studies on MDMA-assisted psychotherapy for PTSD have moved into phase 3 clinical trials, with early results showing the drugs both safe and effective at treating the hard-to-treat condition within three months. More than two-thirds of participants reported complete relief from PTSD symptoms a year after therapy, and most of the remaining one-third of participants saw a dramatic reduction in symptoms. Industry insiders anticipate U.S. drug regulators will approve MDMA for PTSD by year’s end.
Psychedelic Spotlight is your reliable source for the latest stories in the emerging psychedelics industry, covering breakthrough discoveries, investor news and cultural reform.